Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,433 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Phase II trial with S-1 in chemotherapy-naïve patients with gastric cancer. A trial performed by the EORTC Early Clinical Studies Group (ECSG).
Chollet P, Schöffski P, Weigang-Köhler K, Schellens JH, Cure H, Pavlidis N, Grünwald V, De Boer R, Wanders J, Fumoleau P; EORTC Early Clinical Studies Group. Chollet P, et al. Among authors: de boer r. Eur J Cancer. 2003 Jun;39(9):1264-70. doi: 10.1016/s0959-8049(03)00237-5. Eur J Cancer. 2003. PMID: 12763215 Clinical Trial.
Patient preference and pharmacokinetics of oral modulated UFT versus intravenous fluorouracil and leucovorin: a randomised crossover trial in advanced colorectal cancer.
Borner MM, Schoffski P, de Wit R, Caponigro F, Comella G, Sulkes A, Greim G, Peters GJ, van der Born K, Wanders J, de Boer RF, Martin C, Fumoleau P. Borner MM, et al. Among authors: de wit r, de boer rf. Eur J Cancer. 2002 Feb;38(3):349-58. doi: 10.1016/s0959-8049(01)00371-9. Eur J Cancer. 2002. PMID: 11818199 Clinical Trial.
Phase I/II pilot study of intravesical apaziquone (EO9) for superficial bladder cancer.
Puri R, Palit V, Loadman PM, Flannigan M, Shah T, Choudry GA, Basu S, Double JA, Lenaz G, Chawla S, Beer M, Van Kalken C, de Boer R, Beijnen JH, Twelves CJ, Phillips RM. Puri R, et al. Among authors: de boer r. J Urol. 2006 Oct;176(4 Pt 1):1344-8. doi: 10.1016/j.juro.2006.06.047. J Urol. 2006. PMID: 16952628 Clinical Trial.
R(3780) Resonance Interpreted as the 1^{3}D_{1}-Wave Dominant State of Charmonium from Precise Measurements of the Cross Section of e^{+}e^{-}→Hadrons.
Ablikim M, Achasov MN, Adlarson P, Ai XC, Aliberti R, Amoroso A, An MR, An Q, Bai Y, Bakina O, Balossino I, Ban Y, Batozskaya V, Begzsuren K, Berger N, Berlowski M, Bertani M, Bettoni D, Bianchi F, Bianco E, Bloms J, Bortone A, Boyko I, Briere RA, Brueggemann A, Cai H, Cai X, Calcaterra A, Cao GF, Cao N, Cetin SA, Chang JF, Chang TT, Chang WL, Che GR, Chelkov G, Chen C, Chen C, Chen G, Chen HS, Chen ML, Chen SJ, Chen SM, Chen T, Chen XR, Chen XT, Chen YB, Chen YQ, Chen ZJ, Cheng WS, Choi SK, Chu X, Cibinetto G, Coen SC, Cossio F, Cui JJ, Dai HL, Dai JP, Dbeyssi A, de Boer RE, Dedovich D, Deng ZY, Denig A, Denysenko I, Destefanis M, De Mori F, Ding B, Ding XX, Ding Y, Ding Y, Dong J, Dong LY, Dong MY, Dong X, Du SX, Duan ZH, Egorov P, Fan YL, Fang J, Fang SS, Fang WX, Fang Y, Farinelli R, Fava L, Feldbauer F, Felici G, Feng CQ, Feng JH, Fischer K, Fritsch M, Fritzsch C, Fu CD, Fu JL, Fu Y, Fu YW, Gao H, Gao YN, Gao Y, Garbolino S, Garzia I, Ge PT, Ge ZW, Geng C, Gersabeck EM, Gilman A, Goetzen K, Gong L, Gong WX, Gradl W, Gramigna S, Greco M, Gu MH, Gu YT, Guan CY, Guan ZL, Guo AQ, Guo LB, Guo MJ, Guo RP, Guo YP, Guskov A, H XT, Han TT, Han WY, Hao XQ, Harris FA, He KK, He K… See abstract for full author list ➔ Ablikim M, et al. Among authors: de boer re. Phys Rev Lett. 2024 Dec 13;133(24):241902. doi: 10.1103/PhysRevLett.133.241902. Phys Rev Lett. 2024. PMID: 39750337
Family screening for hypertrophic cardiomyopathy: Initial cardiologic assessment, and long-term follow-up of genotype-positive phenotype-negative individuals.
Schoonvelde SAC, Alexandridis GM, Price LB, Schinkel AFL, Hirsch A, Zwetsloot PP, Kammeraad JAE, van Slegtenhorst MA, Verhagen JMA, de Boer RA, Michels M. Schoonvelde SAC, et al. Among authors: de boer ra. Int J Cardiol. 2024 Dec 31;422:132951. doi: 10.1016/j.ijcard.2024.132951. Online ahead of print. Int J Cardiol. 2024. PMID: 39746469 Free article.
Recreational and Occupational Physical Activity and Risk of Adverse Events in Truncating MYBPC3 Founder Variant Carriers.
Hassanzada F, Jansen M, van Lint FHM, Bosman LP, Schmidt AF, Dooijes D, van de Sande D, Miah B, van der Crabben SN, Wilde AAM, Lekanne Deprez RH, de Boer RA, Christiaans I, Jongbloed JDH, Jorstad HT, Asselbergs FW, van Tintelen JP, Baas AF, Te Riele ASJM. Hassanzada F, et al. Among authors: de boer ra. Circ Genom Precis Med. 2024 Dec;17(6):e004561. doi: 10.1161/CIRCGEN.124.004561. Epub 2024 Dec 17. Circ Genom Precis Med. 2024. PMID: 39689185
Key priorities for the implementation of the 2023 ESC Guidelines for the Management of Cardiomyopathies in low resource settings.
Jurcut R, Barriales-Villa R, Biagini E, Garcia-Pavia P, Olivotto I, Protonotarios A, Arbustini E, Mogensen J, Elliott P, Arbelo E, Pablo Kaski J; Members of the Task Force for the 2023 ESC Guidelines for the management of cardiomyopathies. Jurcut R, et al. Eur Heart J Qual Care Clin Outcomes. 2024 Dec 9:qcae103. doi: 10.1093/ehjqcco/qcae103. Online ahead of print. Eur Heart J Qual Care Clin Outcomes. 2024. PMID: 39657995
1,433 results